| Autor: |
Burkhardt UE; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA., Wu CJ; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Oncoimmunology [Oncoimmunology] 2013 Nov 01; Vol. 2 (11), pp. e26587. Date of Electronic Publication: 2013 Oct 10. |
| DOI: |
10.4161/onci.26587 |
| Abstrakt: |
Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. Herein, the implications of this finding for the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are discussed. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
